

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	20609/181 (PD-98076)	09/811,838
	APPLICANT	
	Miller et al.	
	FILING DATE	GROUP ART UNIT
	March 19, 2001	To be Assigned 1626

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE


## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE
88	1	WO 99/47101	09/23/99	WIPO	—	—	
88	2	WO 99/08514	2/25/99	WIPO	—	—	
88	3	WO 98/41213	2/24/99	WIPO	—	—	

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

88	4	Swarthout et al., "Lysophosphatidic Acid: Receptors, Signaling and Survival," <u>CMLS, Cell. Mol. Life Sci.</u> 57:1978-1985 (2000)
88	5	Levine et al., "Lysophosphatidic Acid: A Novel Growth and Survival Factor for Renal Proximal Tubular Cells," The American Physiological Society, pp 575-585 (1997)
88	6	Steiner et al., "Lysophosphatidic Acid Induction of Neuronal Apoptosis and Necrosis," <u>Annals New York Academy of Sciences</u> pp 132-141, YEAR NOT AVAILABLE
88	7	Ediger et al., "Dual Effects of Lysophosphatidic Acid on Human Airway Smooth Muscle Cell Proliferation and Survival," <u>Biochimica et Biophysica Acta</u> 59-67 (2001)
88	8	Fang et al., "Lysophosphatidic Acid Prevents Apoptosis in Fibroblasts Via G <sub>i</sub> -Protein-Mediated Activation of Mitogen- Activated Protein Kinase," <u>Biochem J.</u> 352:135-143 (2000)
88	9	Frankel et al., "Peptide and Lipid Growth Factors Decrease <i>cis</i> -Diamminedichloroplatinum-Induced Cell Death in Human Ovarian Cancer Cells," <u>Clinical Cancer Research</u> 2:1307-1313 (1996)
88	10	Furui et al., "Overexpression of Edg-2/vzg-1 Induces Apoptosis and Anoikis in Ovarian Cancer Cells in a Lysophosphatidic Acid-Independent Manner," <u>Clinical Cancer Research</u> 5:4308-4318 (1999)
EXAMINER		DATE CONSIDERED
Lam J. Stockh		10/28/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449 )	ATTY. DOCKET NO. 20609/181 (PD-98076)	SERIAL NO. 09/811,838
	APPLICANT Miller et al.	
	FILING DATE March 19, 2001	GROUP ART UNIT To be Assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRAN- SLATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		11	Goetzl et al., "Distinctive Expression and Functions of the Type 4 Endothelial Differentiation Gene-Encoded G Protein-Coupled Receptor for Lysophosphatidic Acid in Ovarian Cancer," <u>Cancer Research</u> 59:5370-5375 (1999)
		12	Goetzl et al., "Lysophosphatidic Acid and Sphingosine 1-Phosphate Protection of T Cells from Apoptosis in Association With Suppression of Bax," <u>The American Association of Immunologists</u> pp 2049-2056 (1999)
		13	Koh et al., "Lysophosphatidic Acid Is a Major Serum Noncytokine Survival Factor for Murine Macrophages Which Acts Via The Phosphatidylinositol 3-Kinase Signaling Pathway," <u>J. Clin. Invest.</u> 716-727 (1998)
		14	Holtsberg et al., "Lysophosphatidic Acid and Apoptosis of Nerve Growth Factor-Differentiated PC12 Cells," <u>Journal of Neuroscience Research</u> 53:685-696 (1998)
		15	Holtsberg et al., "Lysophosphatidic Acid Induces Necrosis and Apoptosis in Hippocampal Neurons," <u>Journal of Neurochemistry</u> 66-76 (1998)

EXAMINER 	DATE CONSIDERED 10/28/02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary) (PTO-1449)	APPLICANT DOCKET NO. <b>20609/181 (PD-98076)</b>	SERIAL NO. <b>09/811,838</b>
	APPLICANT <b>Miller et al.</b>	
	FILING DATE <b>March 19, 2001</b>	GROUP ART UNIT <b>1626</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE


## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	1	Kharchenko et al., "Thermal Stability and Antiseize Properties of Some Phosphorus-Containing Lubricating Oil Additives,"
		1974:523954 <u>CAPLUS</u> 81:123954 (1974) (abstract)
	2	Li et al., "Site-Specific Photomodification of DNA by Porphyrin-Oligonucleotide Conjugates Synthesized via Solid Phase
		H-Phosphonate Approach," 1997:164802 <u>CAPLUS</u> 126:141410 (1997) (abstract)
	3	Gibbs, "The Synthesis of Phosphoramidates from Silylphosphites and Azides,"
		1977:453513 <u>CAPLUS</u> 87:53513 (1977) (abstract)
	4	Blume et al., "The Influence of Charge on Bilayer Membranes Calorimetric Investigations of Phosphatidic Acid Bilayers,"
		1980:53762 <u>CAPLUS</u> 92:53762 (1980) (abstract)
	5	Wei et al., "Study on New Amphoteric Surfactants of Phosphates I. Syntheses and Properties,"
		1998:750143 <u>CAPLUS</u> 130:126594 (1998) (abstract)
	6	Badalassi et al., "A Versatile Periodate-Coupled Fluorogenic Assay for Hydrolytic Enzymes,"
		2000:859470 <u>CAPLUS</u> 134:174618 (2000) (abstract)
	7	Bushnev et al., "Synthesis of Rac-3-benzoyl-1-deoxyceramide-1-phosphonic Acid,"
		1983:405425 <u>CAPLUS</u> 99:5425 (1983) (abstract)
EXAMINER		DATE CONSIDERED 10/28/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
 OCT 07 2002  
 TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.  20609/181 (PD-98076)	SERIAL NO.  09/811,838
	APPLICANT  Miller et al.	
	FILING DATE  March 19, 2001	GROUP ART UNIT  1626



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	8	Cates, "Phosphorus-nitrogen Compounds 12 Phosphamidase Studies 2 N-alkylphosphoramidic Acids,"
		1971:471703 <u>CAPLUS</u> 75:71703 (1971) (abstract)
	9	Gasco et al., "Timolol in Lipospheres," 1992:221452 <u>CAPLUS</u> 116:221452 (1992) (abstract)
	10	Avaeva et al., "Hydrolysis of Phosphoric Ester Serine Derivatives Containing Free Amino or Carboxylic Groups,"
		1972:34548 <u>CAPLUS</u> 76:34548 (1972) (abstract)
	11	Valerio et al., "Synthesis of the Simple Peptide Model Ac-Abu (PO3H2)-NHMe,"
		1992:236128 <u>CAPLUS</u> 116:236128 (1992) (abstract)
	12	Ryan et al., "Synthesis, Structure-Activity Relationships, and the Effect of Polyethylene Glycol on Inhibitors of
		Phosphatidylinositol-Specific Phospholipase C from Bacillus Cereus," 1996:618920 <u>CAPLUS</u> 126:16188 (1996) (abstract)
EXAMINER	DATE CONSIDERED	
	10/28/02	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

RECEIVED  
 OCT 07 2002  
 TECH CENTER 1600-2900